Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: A meta-analysis of patient characteristics and placebo response rates in randomized controlled trials

International Clinical Psychopharmacology

Volumn 26, Issue 2, 2011, Pages 69-74

  Iovieno, Nadia ^a,b   Tedeschini, Enrico ^a,c   Ameral, Victoria E ^a   Rigatelli, Marco ^c   Papakostas, George I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

antidepressant; major depressive disorder; medical co morbidity; placebo

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MIANSERIN; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SERTRALINE;

AIDS PATIENT; CANCER PATIENT; COMORBIDITY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; MONOTHERAPY; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIDEPRESSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NERVOUS SYSTEM DISEASES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79951515279     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328340775e     Document Type: Review

References (40)

1. American Psychiatric Association, Task force on Nomenclature and Statistics, American Psychiatric Association, Committee on Nomenclature and Statistics (1980). Diagnostic and statistical manual of mental disorders. Washington: American Psychiatric Assn.
2. American Psychiatric Association, Work Group to Revise DSM-III (1987). Diagnostic and statistical manual of mental disorders: DSM-III-R. Washington, DC: American Psychiatric Association.
3. American Psychiatric Association, American Psychiatric Association, Task Force on DSM-IV (1994). Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association.
4. Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR (2009). Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50:383-391.
5. Brown KW, Levy AR, Rosberger Z, Edgar L (2003). Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med 65:636-643. (Pubitemid 36900260)
6. Ciesla JA, Roberts JE (2001). Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 158:725-730. (Pubitemid 32429839)
7. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ (2001). Association of depression and diabetes complications: a meta-analysis. Psychosom Med 63:619-630. (Pubitemid 32695143)
8. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115-127. (Pubitemid 36469860)
9. Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R (1972). Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 26:57-63.
10. Frasure-Smith N, Lesperance F, Talajic M (1993). Depression following myocardial infarction. Impact on 6-month survival. JAMA 270:1819-1825. (Pubitemid 23301435)
11. Guy W, National Institute of Mental Health (US), Psychopharmacology Research Branch, Early Clinical Drug Evaluation Program (1976). ECDEU assessment manual for psychopharmacology, Rockville, Md., US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psycho-pharmacology Research Branch, Division of Extramural Research Programs.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M (2003). The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry 160:2122-2127. (Pubitemid 39619604)
14. Kanner AM (2003). Depression in epilepsy is much more than a reactive process. Epilepsy Curr 3:202-203.
15. Katon WJ (2003). Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 54:216-226. (Pubitemid 37270614)
16. Katon W, Von Korff M, Ciechanowski P, Russo J, Lin E, Simon G, et al. (2004). Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care 27:914-920. (Pubitemid 38420214)
17. Kim JS (2009). Post-stroke pain. Expert Rev Neurother 9:711-721.
18. Lussier D, Huskey AG, Portenoy RK (2004). Adjuvant analgesics in cancer pain management. Oncologist 9:571-591. (Pubitemid 39332322)
19. Lyketsos CG, Delcampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. (2003). Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60:737-746. (Pubitemid 36818637)
20. Mcdonald WM, Richard IH, Delong MR (2003). Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54:363-375. (Pubitemid 37267863)
21. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
22. Morris PL, Robinson RG, Andrzejewski P, Samuels J, Price TR (1993). Association of depression with 10-year post-stroke mortality. Am J Psychiatry 150:124-129. (Pubitemid 23059176)
23. Nandi A, Beard JR, Galea S (2009). Epidemiologic heterogeneity of common mood and anxiety disorders over the life course in the general population: a systematic review. BMC Psychiatry 9:31.
24. Narasimhan M, Raynor JD, Jones AB (2008). Depression in the medically ill: diagnostic and therapeutic implications. Curr Psychiatry Rep 10:272-279.
25. Papakostas GI, Fava M (2009). Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19:34-40.
26. Papakostas GI, Fava M, editors (2010). Pharmacotherapy for depression and treatment-resistant depression. Singapore: World Scientific Publishing.
27. Partonen T, Sihvo S, Lonnqvist JK (1996). Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry 57:572-575. (Pubitemid 27056898)
28. Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D, Evans DL (1994). Mood disorders in HIV infection: prevalence and risk factors in a none-picenter of the AIDS epidemic. Am J Psychiatry 151:233-236. (Pubitemid 24053105)
29. Posternak MA, Zimmerman M, Keitner GI, Miller IW (2002). A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 159:191-200. (Pubitemid 34126894)
30. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, et al. (2008). Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry 65:870-880.
31. Spitzer RL, Endicott J, Robins E (1978). Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 35:773-782. (Pubitemid 9064061)
32. Subramaniam M, Sum CF, Pek E, Stahl D, Verma S, Liow PH, et al. (2009). Co-morbid depression and increased health care utilisation in individuals with diabetes. Gen Hosp Psychiatry 31:220-224.
33. Sullivan PF, Joyce PR (1994). Effects of exclusion criteria in depression treatment studies. J Affect Disord 32:21-26. (Pubitemid 24277403)
34. Trivedi MH, Fava M,Wisniewski SR, Thase ME, Quitkin F,Warden D, et al. (2006). Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243-1252.
35. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287: 1840-1847. (Pubitemid 34303629)
36. Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, et al. (2009). Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 166:599-607.
37. Zetin M, Hoepner CT (2007). Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol 27:295-301. (Pubitemid 46763313)
38. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE (2000). Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 160:1818-1823. (Pubitemid 30418820)
39. Zimmerman M, Mattia JI, Posternak MA (2002). Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 159:469-473. (Pubitemid 34184745)
40. Zimmerman M, Chelminski I, Posternak MA (2004). Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis 192:87-94. (Pubitemid 38248899)